69 articles
Aditya Bardia
Aditya Bardia is an American medical oncologist specializing in breast cancer therapeutics, especially antibody–drug conjugates, and a professor and breast oncology program director at UCLA since 2024.
Alfredo Berruti
Alfredo Berruti is an Italian medical oncologist, full professor at the University of Brescia and chief of medical oncology at Spedali Civili Hospital, known for adrenocortical carcinoma research.
Amit M. Oza
Amit M. Oza, also cited as Amit Oza, is a medical oncologist at Princess Margaret Cancer Centre in Toronto who runs clinical trials in gynecologic cancers, especially ovarian cancer.
Andreas du Bois
Andreas du Bois is a German gynecologic oncologist who founded the AGO Study Group in 1993 and led landmark ovarian cancer trials including LION and DESKTOP III.
Ann H. Partridge
Ann H. Partridge is an American medical oncologist at Dana-Farber Cancer Institute in Boston, a Harvard professor known for research on breast cancer in young women.
Ariel Rösler
Ariel Rösler is an Israeli endocrinologist at Hadassah Hebrew University Medical Center in Jerusalem, known for steroid biosynthesis research and a 1998 GnRH-analog treatment for paraphilia.
Aron Goldhirsch
Aron Goldhirsch (1946–2020) was a medical oncologist who specialized in breast cancer, working at the European Institute of Oncology in Milan and co-founding the Breast International Group in 1996.
Bradley J. Monk
Bradley J. Monk is an American gynecologic oncologist whose trials of bevacizumab, PARP inhibitors, and immunotherapy in cervical and ovarian cancer have been described as practice-changing.
Carlos L. Arteaga
Carlos L. Arteaga is an American medical oncologist and breast cancer drug resistance researcher who directs the Simmons Comprehensive Cancer Center at UT Southwestern in Dallas since 2017.
Charles E. Geyer
Charles E. Geyer is an American oncologist, Chief Scientific Officer of the NSABP Foundation and chief of medical oncology at UPMC Hillman, known for the KATHERINE and OlympiA breast cancer trials.
Charles L. Loprinzi
Charles L. Loprinzi is an American medical oncologist at Mayo Clinic in Rochester, Minnesota, known for hot-flash trials and the 2016 olanzapine antiemetic study that changed chemotherapy nausea guidelines.
Christoph Zielinski
Christoph Zielinski is an Austrian medical oncologist who led clinical oncology at the Medical University of Vienna from 2001 to 2017 and founded the Central European Cooperative Oncology Group.
Clifford A. Hudis
Clifford A. Hudis is an American medical oncologist who led breast cancer care at Memorial Sloan Kettering and has been chief executive of ASCO since 2016.
Cristiana Sessa
Cristiana Sessa is a Swiss-based medical oncologist specializing in gynecologic cancers, known for European guidelines on ovarian cancer and early-phase new-drug development at the Oncology Institute of Southern Switzerland.
David S. Alberts
David S. Alberts, also known as David Alberts, was an American oncologist at the University of Arizona whose 1996 trial established intraperitoneal cisplatin for advanced ovarian cancer.
Edith A. Perez
Edith A. Perez is an American oncologist and breast cancer researcher who led the NCCTG N9831 adjuvant trastuzumab trial and spent two decades at Mayo Clinic in Florida.
Elisabeth G.E. de Vries
Elisabeth G.E. de Vries, known as Liesbeth de Vries, is a Dutch medical oncologist and professor at the University Medical Center Groningen who pioneered cancer drug imaging.
Eric P. Winer
Eric P. Winer is an American medical oncologist specializing in breast cancer who became Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital in 2022.
Éric Pujade-Lauraine
Éric Pujade-Lauraine is a French gynecologic oncologist and professor of medical oncology who heads the Women Cancer department at Hôpital Hôtel-Dieu in Paris and founded the GINECO trial group.
Fátima Cardoso
Fátima Cardoso is a Portuguese medical oncologist specializing in breast cancer, known for leading the MINDACT trial and creating Portugal's first certified Breast Unit in Lisbon.
Franco M. Muggia
Franco M. Muggia (1936–2021) was an Italian-born American medical oncologist at the National Cancer Institute and NYU, known for the dexrazoxane cardioprotection trial and ovarian cancer therapeutics.
Frédéric Amant
Frédéric Amant (born 1967) is a Belgian gynecologic oncologist who heads Gynecological Oncology at KU Leuven and founded INCIP, showing chemotherapy during pregnancy can be safe.
Gabriel N. Hortobágyi
Gabriel N. Hortobágyi is a breast medical oncologist at The University of Texas MD Anderson Cancer Center in Houston, where he has served on the faculty since 1971 and led major breast cancer drug trials.
George Coukos
George Coukos is a physician-scientist in tumor immunology and cellular immunotherapy who discovered spontaneous antitumor immunity in ovarian cancer and directs the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine.
George W. Sledge
George W. Sledge is an American medical oncologist who spent 30 years at Indiana University, led the TAILORx and MONARCH 2 breast cancer trials, and served as ASCO president.
Gianni Bonadonna
Gianni Bonadonna (1934–2015) was an Italian medical oncologist at the Istituto Nazionale Tumori in Milan who designed the CMF breast cancer and ABVD Hodgkin lymphoma regimens.
Giuseppe Curigliano
Giuseppe Curigliano is an Italian medical oncologist who leads early drug development at the European Institute of Oncology in Milan and specializes in breast cancer.
Harold J. Burstein
Harold J. Burstein is an American medical oncologist specializing in breast cancer, a professor at Harvard Medical School, and a Dana-Farber clinician known for NEJM reviews and treatment guidelines.
Hope S. Rugo
Hope S. Rugo is an American medical oncologist specializing in breast cancer, known for the phase 3 CAPItello-291 and ASCENT trials and, since 2025, chief of breast medical oncology at City of Hope.
Ian E. Krop
Ian E. Krop is an American medical oncologist and breast cancer drug-development researcher who joined Yale Cancer Center in 2022 after 16 years at Dana-Farber Cancer Institute.